09 June 2015 – 11 June 2015
London, UK
This event will highlight and discuss recent advances in strategies for controlling stem cell fate and reprogramming (including new insights into the molecular basis of pluripotency and differentiation) together with the progress towards therapeutic and bioprocessing.
This event has CPD accreditation
This event has an open abstract session. Abstracts can be submitted on any subject related to Stem Cells
The Deadline for abstract submissions for oral presentation is March 10th 2015
Abstracts for poster presentation only can be submitted up to two weeks before the event.
You can download the instructions for authors at
Who Should Attend
Anyone with an interest in stem cell biology, differentiation and use in biomedicine should attend this event, including, but not exclusively people from:
Biotech and Pharma Industry: CEOs, Chief Scientists, Group Heads, Senior and Junior Scientists, Research Managers
Academic and Research Institutes: Group and Lab Heads, Postdoctoral Scientists and Research Students
Amniotic Fluid Stem Cells Biochemical engineering Bioprocess; Bioreactor bone marrow capping cardiomyocytes cell therapy Characterisation Chemical Reprogramming culture CYP p450 delivery DNA methylation drug Drug Metabolism Embryonic Stem cells Epigenetics ESGRO 2i glioblastoma GMP heart heart disease hepatocyte hESC High-throughput efficiency histone homing human embryonic stem cell human neural stem cells human pluripotent stem cells in vitro transcription Induced pluripotency Induced Pluripotent Stem Cells iPS cells iPSC liver liver; beta-cell manufacturing Mesenchyma stem cell microRNA migration modified nucleotides Nanog nanomaterials neural stem cell oxidative stress pancreas Parkinsons Pluripotency Regenerative Medicine Pluripotency; reprogramming; chromatin signatures; DNA replication timing; histone acetyltransferase p30 pluripotent stem cell Pluripotentcy poly(A) tail Regenerative Medicine reprogramming Stable Karyoytpe stem cell research stem cells STEMCCA supply chain synthetic mRNA as drug analogue toxicity translation Wnt signalling
